AstraZeneca will list its shares on the New York Stock Exchange, while maintaining its UK headquarters, its main listing on the London Stock Exchange and its tax base, according to Euronews.
The Anglo-Swedish pharmaceutical giant stated that it will replace its current American Depositary Receipts (ADRs) on Nasdaq with a direct listing of common shares on the New York Stock Exchange. Concurrently, AstraZeneca will maintain its primary listing on the London Stock Exchange, as well as its secondary listing on the Stockholm Stock Exchange.
AstraZeneca stated that the change aims to facilitate U.S. investors’ access to its stock and reduce the costs and complexity associated with ADRs.
